ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Clinical trials for ERYTHROPOIETIC PROTOPORPHYRIA (EPP) explained in plain language.
Never miss a new study
Get alerted when new ERYTHROPOIETIC PROTOPORPHYRIA (EPP) trials appear
Sign up with your email to follow new studies for ERYTHROPOIETIC PROTOPORPHYRIA (EPP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare sun allergy: bitopertin offered to patients with no options
Disease control AVAILABLEThis expanded access program provides bitopertin (DISC-1459) to patients aged 12 and older with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) who have no satisfactory treatment options in the US. The goal is to offer access and gather safety information. Pa…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New study aims to unlock mysteries of rare sun allergy disorders
Knowledge-focused Recruiting nowThis observational study is gathering information on how erythropoietic protoporphyria (EPP) and X-linked porphyria (XLP) affect people aged 12 and older. Over 6 months, researchers will track symptoms, light exposure, and blood levels of protoporphyrin IX (PPIX) in 50 participan…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Sponsor: Portal Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC